SynthesisEuropean journal of preventive cardiology2017
Genetic invalidation of Lp-PLA
Open access · bronzeAbstract readSystematic Review
In one paragraph
Synthesis in European journal of preventive cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies.Immunological reviews · 2026Review
- Functionally informed cis and trans proteome-wide association studies prioritize disease-critical genes.Research square · 2026Article
- Functionally informed cis and trans proteome-wide association studies prioritize disease-critical genes.medRxiv : the preprint server for health sciences · 2026Article
- Lysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation.Frontiers in cardiovascular medicine · 2026Review
- Lipoprotein-associated phospholipase A2 (Lp-PLA2): a key hub linking lipid metabolism and immune inflammation.Frontiers in immunology · 2026Review
- Search for common genetic variants to allow reliable Mendelian randomization investigations into ketone metabolism.European journal of epidemiology · 2025Article
- Apolipoprotein B-containing lipoproteins in atherogenesis.Nature reviews. Cardiology · 2025Review
- rs1051931 Nonsynonymous Polymorphism of Platelet-Activating Factor Acetylhydrolase GeneInternational journal of molecular sciences · 2025Article
- Using proteomics to identify the mechanisms underlying the benefits of statins on ischemic heart disease.NPJ cardiovascular health · 2024Article
- Mendelian randomization for cardiovascular diseases: principles and applications.European heart journal · 2023Review
- Using genetic association data to guide drug discovery and development: Review of methods and applications.American journal of human genetics · 2023Review
- Tag-SNPs in Phospholipase-Related Genes Modify the Susceptibility to Nephrosclerosis and its Associated Cardiovascular Risk.Frontiers in pharmacology · 2022Article
- On the present and future role of Lp-PLAArchives of medical science : AMS · 2021Article
- Red Blood Cells and Hemoglobin in Human Atherosclerosis and Related Arterial Diseases.International journal of molecular sciences · 2020Review
- Lipoprotein-associated phospholipase A2: The story continues.Medicinal research reviews · 2020Review
- Re-thinking Alzheimer's disease therapeutic targets using gene-based tests.EBioMedicine · 2018Article
- Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis.Molecular therapy. Methods & clinical development · 2018Article
- Disconnect Between Genes Associated With Ischemic Heart Disease and Targets of Ischemic Heart Disease Treatments.EBioMedicine · 2018Article
- Lipoprotein-associated phospholipase AAtherosclerosis · 2018Article
Corrections and comments
- Commented on by
Authors and funding
66 authors at 20 institutions in 15 countries.
John M Gregson1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Daniel F Freitag1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Praveen Surendran1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Nathan O Stitziel2 Departments of Medicine and Genetics, Washington University School of Medicine, St Louis, USA.
Rajiv Chowdhury1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Stephen Burgess1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Stephen Kaptoge1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Pei Gao1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
James R Staley1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Peter Willeit3 Department of Public Health and Primary Care, University of Cambridge, UK.
Sune F Nielsen5 Copenhagen University Hospital, University of Copenhagen, Denmark.
Muriel Caslake6 University of Glasgow, UK.
Stella Trompet7 Leiden University Medical Centre, Netherlands.
Linda M Polfus8 University of Texas Health Science Center Houston, USA.
Kari Kuulasmaa9 THL-National Institute for Health and Welfare, Helsinki, Finland.
Jukka Kontto9 THL-National Institute for Health and Welfare, Helsinki, Finland.
Markus Perola10 Institute of Molecular Medicine FIMM, University of Helsinki, Finland.
Stefan Blankenberg12 Department of General and Interventional Cardiology, University Heart Centre Hamburg, Germany.
Giovanni Veronesi14 Research Centre, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.
Francesco Gianfagna14 Research Centre, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.
Satu Männistö9 THL-National Institute for Health and Welfare, Helsinki, Finland.
Akinori Kimura16 Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Japan.
Honghuang Lin17 Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, USA.
Dermot F Reilly19 Merck Research Laboratories, Genetics and Pharmacogenomics, Boston, USA.
Mathias Gorski20 Department of Genetic Epidemiology, University of Regensburg, Germany.
Vladan Mijatovic22 Department of Life and Reproduction Sciences, University of Verona, Italy.
CKDGen consortium
Patricia B Munroe23 Clinical Pharmacology and The Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
Georg B Ehret25 Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA.
International Consortium for Blood Pressure
Alex Thompson28 UCB, Brussels, Belgium.
Maria Uria-Nickelsen29 Clinical Research, Pfizer Worldwide R&D, Cambridge, USA.
Anders Malarstig30 Clinical Research, Pfizer Worldwide R&D, Sollentuna, Sweden.
Abbas Dehghan31 Department of Epidemiology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
CHARGE inflammation working group
Thomas F Vogt32 Merck Research Laboratories, Cardiometabolic Disease, Kenilworth, USA.
Taishi Sasaoka16 Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Japan.
Fumihiko Takeuchi34 Department of Gene Diagnostics and Therapeutics, Research Institute, National Centre for Global Health and Medicine, Tokyo, Japan.
Norihiro Kato34 Department of Gene Diagnostics and Therapeutics, Research Institute, National Centre for Global Health and Medicine, Tokyo, Japan.
Yoshiji Yamada35 Department of Human Functional Genomics, Life Science Research Centre, Mie University, Japan.
Frank Kee36 UKCRC Centre of Excellence for Public Health, Queens University, Belfast, Ireland.
Martina Müller-Nurasyid37 Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Centre for Environmental Health, Neuherberg, Germany.
Jean Ferrières41 Department of Epidemiology, UMR 1027-INSERM, Toulouse University-CHU Toulouse, France.
Dominique Arveiler42 Department of Epidemiology and Public Health, EA 3430, University of Strasbourg and Strasbourg University Hospital, France.
Philippe Amouyel43 Department of Epidemiology and Public Health, Institut Pasteur de Lille, France.
Veikko Salomaa9 THL-National Institute for Health and Welfare, Helsinki, Finland.
Eric Boerwinkle44 Human Genetics Center, University of Texas Health Science Center at Houston, USA.
Simon G Thompson1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Ian Ford6 University of Glasgow, UK.
J Wouter Jukema7 Leiden University Medical Centre, Netherlands.
Naveed Sattar6 University of Glasgow, UK.
Chris J Packard6 University of Glasgow, UK.
Abdulla Al Shafi Majumder45 National Institute of Cardiovascular Diseases, Sher-e-Bangla Nagar, Dhaka, Bangladesh.
Dewan S Alam46 Centre for Global Health Research, St Michael Hospital, Toronto, Canada.
Panos Deloukas47 William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
Heribert Schunkert39 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
Nilesh J Samani49 Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit, UK.
Sekar Kathiresan50 Broad Institute, Cambridge and Massachusetts General Hospital, Boston, USA.
MICAD Exome consortium
Børge G Nordestgaard5 Copenhagen University Hospital, University of Copenhagen, Denmark.
Danish Saleheen51 University of Pennsylvania, Philadelphia, USA.
Joanna Mm Howson1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Emanuele Di Angelantonio1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
Adam S Butterworth1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
John Danesh1 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
EPIC-CVD consortium and the CHD Exome+ consortium
University of Cambridge · GBFinnish Institute for Health and Welfare · FILeiden University Medical Center · NLQueen Mary University of London · GBTokyo Medical and Dental University · JPBroad Institute · USInserm · FRInstitut Pasteur de Lille · FRMerck & Co., Inc., Rahway, NJ, USA (United States) · USMie University · JPUniversity of Copenhagen · DKUniversity of Glasgow · GBUniversity of Insubria · ITBoston University · USCentre for Global Health Research · CAErasmus University Rotterdam · NLHelmholtz Zentrum München · DEInnsbruck Medical University · ATJohns Hopkins University · USNational Center for Global Health and Medicine · JP
Funding
British Heart Foundation RG/14/5/30893British Heart Foundation SP/09/002European Research Council 268834Medical Research Council G0800270Medical Research Council MC_UU_00002/7Wellcome Trust 204623/Z/16/Z
Abstract
Aims Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A
Indexed as
Molecular Targeted Therapy1-Alkyl-2-acetylglycerophosphocholine EsteraseAdultAgedAllelesBenzaldehydesBiphenyl CompoundsCase-Control StudiesCoronary DiseaseDiethylaminesFemaleGene Expression RegulationGenotypeHumansMaleMiddle Aged1-Alkyl-2-acetylglycerophosphocholine EsteraseBenzaldehydesBiphenyl CompoundsdarapladibDiethylaminesOximesPhospholipase A2 InhibitorsPyrimidinonesSulfidescoronary heart diseasedarapladibHuman geneticslipoprotein-associated phospholipase A2target validation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.